131 results
8-K
EX-99.1
CPMV
Mosaic ImmunoEngineering Inc.
29 Apr 24
Regulation FD Disclosure
8:00am
assets to be acquired include cancer and ocular disease programs, including regulatory and clinical packages and access to Oncotelic’s AI platform … , which can result in a robust anti-cancer immune response. In addition to the clinical stage assets, Mosaic will have non-exclusive access
8-K
CPMV
Mosaic ImmunoEngineering Inc.
29 Apr 24
Regulation FD Disclosure
8:00am
regulatory and clinical packages. The Company will also have access to Oncotelic’s proprietary Artificial Intelligence (“AI”) technologies for identifying
8-K
EX-10.1
CPMV
Mosaic ImmunoEngineering Inc.
29 Apr 24
Regulation FD Disclosure
8:00am
accounting, legal and other advisers, with reasonable access to the information that such party reasonably requests for purposes of evaluating … for CA4P; and 2) non-exclusive access to AI technologies and IP for the development of CA4P for these indications including biomarker and patient
8-K
EX-10.1
uo1gonv3sd
22 Feb 22
Entry into a Material Definitive Agreement
5:20pm
DEF 14C
49do xo4w8m3xt
25 Jun 21
Information statement
12:05pm
PRE 14C
nj23sl60cynz81pj7w74
15 Jun 21
Preliminary information
4:00pm
8-K
EX-10.1
rnfgaj e5m9hgi8
10 May 21
Entry into a Material Definitive Agreement
4:03pm